| CRNX Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CRNX shares outstanding history going back to 7/18/2018:
Also see: CRNX Market Cap History CRNX YTD Return |
CRNX Shares Outstanding History — Crinetics Pharmaceuticals Share Count Over Time
As of 7/22/2026 Crinetics Pharmaceuticals has 106.07 million CRNX shares outstanding. Investors often track the CRNX shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows CRNX share count trends over time, with 35 historical shares outstanding datapoints presented, dating back to 7/18/2018.
| CRNX Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CRNX Historical Shares Outstanding: +21.67% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRNX Stock Price Chart |
| About Crinetics Pharmaceuticals Inc |
| Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. We show 35 historical shares outstanding datapoints in our coverage of CRNX's shares outstanding history. Understanding the changing numbers of CRNX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CRNX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CRNX by allowing them to research CRNX shares outstanding history as well as any other stock in our coverage universe. |
| CRNX Current Stock Quote |
Quotes delayed 20 minutes  Free CRNX Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| CRNX Share Performance |
| Shares Outstanding Peers |
| Crinetics Pharmaceuticals (CRNX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
CRTX Shares Outstanding History CRVL Shares Outstanding History CRVO Shares Outstanding History CRVS Shares Outstanding History CRY Shares Outstanding History CSBR Shares Outstanding History CSII Shares Outstanding History CSTL Shares Outstanding History CSU Shares Outstanding History CTIC Shares Outstanding History More Healthcare companies » |
CRNX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
